Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Terns Pharmaceuticals, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
10/10/2023 8-K Quarterly results
10/10/2023 SC 13G/A FIL Ltd reports a 8.4% stake in TERNS PHARMACEUTICALS INC
10/04/2023 SC 13G/A Flynn James E reports a 0% stake in Terns Pharmaceuticals, Inc.
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates - Terns reported positive top-line data from the Phase 2a DUET trial of TERN-501 in NASH, with TERN-501 meeting all primary and secondary endpoints - TERN-701 Phase 1 clinical trial for CML on track to initiate in second half of 2023; enrollment progress from ongoing China Phase 1 clinical trial presented at 2023 ASCO Annual Meeting - TERN-601 program in obesity highlighted in preclinical data presented at ADA’s 83rd Annual Scientific Meeting; on track to initiate Phase 1 clinical trial in second half of 2023 - Cash, cash equivalents and marketable securities of $286 million expected to provide runway into 2026 FOSTER CITY, Calif., August 8, 2023 – Terns Pharmaceuticals, Inc. , a clinical-stage biopha..."
08/03/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Terns Pharmaceuticals Announces Leadership Transition"
07/28/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
06/02/2023 4 Vignola Mark J. (CFO) has filed a Form 4 on Terns Pharmaceuticals, Inc.
Txns: Bought 9,997 shares @ $1.41, valued at $14.1k
06/02/2023 4 Yoon Seokho Bryan (COO and General Counsel) has filed a Form 4 on Terns Pharmaceuticals, Inc.
Txns: Bought 9,997 shares @ $1.41, valued at $14.1k
06/02/2023 4 Sundaram Senthil Vel (CEO) has filed a Form 4 on Terns Pharmaceuticals, Inc.
Txns: Bought 2,111 shares @ $1.41, valued at $3k
05/15/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Terns Pharmaceuticals, Inc. $150,000,000 SHARES of Common Stock, Par Value $0.0001 SALES AGREEMENT",
"Letter re: Prospectus Supplement to Registration Statement on Form S-3"
05/15/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/15/2023 8-K Quarterly results
Docs: "Terns Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Updates - Top-line data from Phase 2a DUET clinical trial of TERN-501 in NASH expected in third quarter of 2023 - TERN-701 Phase 1 trial for CML on track to initiate in the U.S. in second half of 2023; enrollment progress update from ongoing China Phase 1 trial expected at the 2023 ASCO Annual Meeting - TERN-601 program in obesity on track to initiate Phase 1 clinical trial in second half of 2023 with initial proof of concept data anticipated in 2024 - Cash, cash equivalents and marketable securities of $298 million expected to provide runway into 2026 FOSTER CITY, Calif., May 15, 2023 – Terns Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product ca..."
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/29/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
03/27/2023 10-K Annual Report for the period ended December 31, 2022
03/27/2023 8-K Quarterly results
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
03/02/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Terns Pharmaceuticals Provides Program Updates and Announces Participation at Upcoming March Investor Conferences Completes enrollment in Phase 2a DUET clinical trial of TERN-501 as a treatment for NASH with top-line results expected in third quarter of 2023 On track to initiate U.S. clinical trial for TERN-701 in CML in second half of 2023; enrollment progress update from ongoing China Phase 1 trial expected at a major upcoming oncology conference IND-enabling activities for TERN-601 ongoing; on track to initiate first-in-human clinical trial in obesity in second half of 2023 Cash and cash equivalents expected to provide runway into 2026 FOSTER CITY, Calif., March 2, 2023 -- Terns Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule p..."
02/14/2023 SC 13G/A Venrock Healthcare Capital Partners III, L.P. reports a 7.7% stake in Terns Pharmaceuticals, Inc.
02/14/2023 SC 13G/A Fairmount Funds Management LLC reports a 9.9% stake in Terns Pharmaceuticals, Inc.
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/13/2023 EFFECT Form EFFECT - Notice of Effectiveness:
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A FMR LLC reports a 14.9% stake in TERNS PHARMACEUTICALS INC
02/09/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/08/2023 SC 13G/A BML Investment Partners, L.P. reports a 0% stake in Terns Pharmaceuticals, Inc.
02/08/2023 SC 13G/A BML Investment Partners, L.P. reports a 0% stake in Terns Pharmaceuticals, Inc.
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy